Pharmaceutical company AcuCort has published its newsletter for June 2026. In the newsletter, the Company provides an update on its participation in BIO International Convention in San Diego, the world's leading partnering conference for life science companies.
Ahead of the conference, AcuCort has scheduled more than 50 meetings with potential partners. The objective is to identify and advance discussions with relevant collaboration partners in preparation for the planned New Drug Application (NDA) submission for Zeqmelit® in 2026.
The newsletter is available here:
Would you like to receive future newsletters directly in your inbox? Sign up here:
https://www.acucort.se/EN/media/subscribe/
For further information:
Jonas Jönmark, CEO, AcuCort AB
Phone: 070 365 5400
E-mail: jonas.jonmark@acucort.se
About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland, where the product is also marketed. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.